Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM4B | O94953 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19160453 | 0.88 | KDM1A (0.41) | KDM1AEGFR | |
| SCHEMBL19160412 | 0.80 | KDM4A (0.41) | KDM1AKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL19160487 | 0.77 | KDM1A (0.43) | KDM1AKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL19160441 | 0.77 | EGFR (0.37) | KDM1AEGFR | |
| SCHEMBL19160426 | 0.76 | KDM1A (0.37) | KDM1AEGFR | |
| SCHEMBL6833209 | 0.73 | EGFR (0.42) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL19160365 | 0.72 | KDM1A (0.39) | KDM1AEGFRDYRK1AGSK3B | |
| SCHEMBL19160397 | 0.72 | KDM1A (0.39) | KDM1AEGFR | |
| SCHEMBL19160457 | 0.71 | AXL (0.42) | KDM1AEGFRPDPK1 | |
| SCHEMBL19160630 | 0.71 | KDM1A (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | UNIV COLUMBIA (US) | 2020-07-09 | — | — | US | disclosed |
| US-10626124-B2 | — | — | 2020-04-21 | — | — | US | disclosed |
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | NY STATE PSYCHIATRIC INSTITUTE | 2019-04-18 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
| US-10626124-B2 | — | MAPT, SQSTM1, TFEB | KDM1A 3578/4885KDM4C 3232/4885KDM4A 3505/4885 |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM1A 3990/4885KDM4C 3959/4885KDM4A 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.